CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ 22,806	$ (46,415)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	367	869
Non-cash lease cost	969	678
Impairment of assets	5,306	635
Share-based compensation	7,932	9,123
Unrealized foreign currency transaction (gain) loss	0	10
Accretion of premium (discount) on marketable securities	0	13
Change in fair value of derivative liabilities	0	(917)
Non-cash interest expense associated with the sale of future royalties	0	2,605
Loss on extinguishment of liability related to the sale of future royalties	0	3,581
Changes in operating assets and liabilities:
Collaboration receivable, current and non-current - related party	(95,742)	0
Other receivables	(461)	1,547
Prepaid expenses and other current assets	(799)	5,242
Other assets	(1)	(3)
Accounts payable	761	(484)
Accrued expenses and other current liabilities	(2,416)	(5,377)
Deferred revenue, current and non-current	29,009	21,892
Other long-term liabilities	(9)	(42)
Operating lease liabilities	(1,104)	(688)
Income taxes payable	387	0
Net cash used in operating activities	(32,995)	(7,731)
Cash flows from investing activities:
Purchases of marketable securities	0	(26,970)
Proceeds from maturities of marketable securities	0	60,777
Net cash provided by investing activities	0	33,807
Cash flows from financing activities:
Repayment of liability related to the sale of future royalties	0	(54,485)
Proceeds from stock option exercises	0	420
Net cash provided by financing activities	221	(29,553)
Net increase (decrease) in cash and cash equivalents	(32,774)	(3,477)
Cash and cash equivalents at beginning of period	109,107	112,584
Cash and cash equivalents at end of period	76,333	109,107
Supplemental disclosure of non-cash activities:
Cash paid for income taxes	2,212	0
Proceeds from the issuance of common stock, net of commissions
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	221	14,234
Proceeds from the issuance of common stock related to the GSK Share Purchase Agreement
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	$ 0	$ 10,278